Metabolic Dysfunction-Associated Steatohepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Metabolic Dysfunction-Associated Steatohepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A28014

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Metabolic Dysfunction-Associated Steatohepatitis - Introduction

    4.1 Overview
    4.2 Regulatory Process
    4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
    4.4 Market Overview (2019-2024) and Forecast (2025-2035)
    4.5 Competitive Intelligence
5 Metabolic Dysfunction-Associated Steatohepatitis - Disease Overview
    5.1    Introduction
    5.2    Symptoms and Diagnosis
    5.3    Pathophysiology
    5.4    Causes and Risk Factors
    5.5    Treatment
6 Patient Journey
7 Metabolic Dysfunction-Associated Steatohepatitis - Epidemiology and Patient Population

    7.1    Epidemiology - Key Insights    
    7.2    Epidemiology Scenario - Top 7 Markets
              7.2.1 Epidemiology Scenario (2019-2024)        
              7.2.2 Epidemiology Forecast (2025-2035)    
        7.2.3 Epidemiology by Age (2019-2035)
              7.2.4 Epidemiology by Gender (2019-2035)    
    7.2.5 Diagnosed Cases (2019-2035)
        7.2.6 Patient Pool/Treated Cases (2019-2035)        
    7.3    Epidemiology Scenario - United States    
        7.3.1 Epidemiology Scenario (2019-2024)    
        7.3.2 Epidemiology Forecast (2025-2035)    
        7.3.3 Epidemiology by Age (2019-2035)    
              7.3.4 Epidemiology by Gender (2019-2035)
        7.3.5 Diagnosed Cases (2019-2035)
        7.3.6 Patient Pool/Treated Cases (2019-2035)    
    7.4    Epidemiology Scenario - Germany    
        7.4.1 Epidemiology Scenario (2019-2024)    
        7.4.2 Epidemiology Forecast (2025-2035)    
        7.4.3 Epidemiology by Age (2019-2035)
    7.4.4 Epidemiology by Gender (2019-2035)
           7.4.5 Diagnosed Cases (2019-2035)
        7.4.6 Patient Pool/Treated Cases (2019-2035)
    7.5    Epidemiology Scenario - France    
         7.5.1 Epidemiology Scenario (2019-2024)
        7.5.2 Epidemiology Forecast (2025-2035)
        7.5.3 Epidemiology by Age (2019-2035)
    7.2.4 Epidemiology by Gender (2019-2035)
       7.5.5 Diagnosed Cases (2019-2035)
               7.5.6 Patient Pool/Treated Cases (2019-2035)
     7.6    Epidemiology Scenario - United Kingdom
             7.6.1 Epidemiology Scenario (2019-2024)    
             7.6.2 Epidemiology Forecast (2025-2035)    
             7.6.3 Epidemiology by Age (2019-2035)    
             7.6.4 Epidemiology by Gender (2019-2035)    
             7.6.5 Diagnosed Cases (2019-2035)
             7.6.6 Patient Pool/Treated Cases (2019-2035)    
    7.7    Epidemiology Scenario - Italy    
          7.7.1 Epidemiology Scenario (2019-2024)    
          7.7.2 Epidemiology Forecast (2025-2035)    
          7.7.3 Epidemiology by Age (2019-2035)    
          7.7.4 Epidemiology by Gender (2019-2035)    
          7.7.5 Diagnosed Cases (2019-2035)
          7.7.6 Patient Pool/Treated Cases (2019-2035)
    7.8    Epidemiology Scenario - Spain    
          7.8.1 Epidemiology Scenario (2019-2024)    
          7.8.2 Epidemiology Forecast (2025-2035)    
          7.8.3 Epidemiology by Age (2019-2035)    
          7.8.4 Epidemiology by Gender (2019-2035)    
          7.8.5 Diagnosed Cases (2019-2035)
          7.8.6 Patient Pool/Treated Cases (2019-2035)
    7.9    Epidemiology Scenario - Japan    
         7.9.1 Epidemiology Scenario (2019-2024)    
         7.9.2 Epidemiology Forecast (2025-2035)    
         7.9.3 Epidemiology by Age (2019-2035)
         7.9.4 Epidemiology by Gender (2019-2035)
         7.9.5 Diagnosed Cases (2019-2035)
         7.9.6 Patient Pool/Treated Cases (2019-2035)
8 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Treatment Algorithm, Guidelines, and Medical Practices
    8.1    Guidelines, Management and Treatment
    8.2    Treatment Algorithm    
9   Metabolic Dysfunction-Associated Steatohepatitis Treatment - Unmet Needs    
10 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Key Endpoints of Treatment
11 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Products        

11.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Drugs Across the Top 7 Markets    
         11.1.1 Rezdiffra (Resmetirom) - Madrigal Pharmaceuticals
                 11.1.1.1 Drug Overview    
            11.1.1.2 Mechanism of Action    
            11.1.1.3 Clinical Trial Results    
            11.1.1.4 Safety and Efficacy
            11.1.1.5 Regulatory Status

Complete list to be provided in the final report.

12 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Pipeline Products    
    12.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegozafermin – 89bio
               12.1.1.1 Drug Overview    
               12.1.1.2 Mechanism of Action    
               12.1.1.3 Clinical Trial Results    
               12.1.1.4 Safety and Efficacy
               12.1.1.5 Regulatory Status
12.1.2 Efruxifermin – Akero Therapeutics
               12.1.2.1 Drug Overview
               12.1.2.2 Mechanism of Action
               12.1.2.3 Clinical Trial Results
               12.1.2.4 Safety and Efficacy  
               12.1.2.5 Regulatory Status 
12.1.3 Miricorilant – Corcept Therapeutics
               12.1.3.1 Drug Overview
               12.1.3.2 Mechanism of Action
               12.1.3.3 Clinical Trial Results
               12.1.3.4 Safety and Efficacy                
               12.1.3.5 Regulatory Status  
12.1.4 ALG-055009 – Aligos Therapeutics
               12.1.4.1 Drug Overview
               12.1.4.2 Mechanism of Action
               12.1.4.3 Clinical Trial Results
               12.1.4.4 Safety and Efficacy                
               12.1.4.5 Regulatory Status  
12.1.5 ALN-HSD – Regeneron Pharmaceuticals
               12.1.5.1 Drug Overview
               12.1.5.2 Mechanism of Action
               12.1.5.3 Clinical Trial Results
               12.1.5.4 Safety and Efficacy                
               12.1.5.5 Regulatory Status  

Complete list to be provided in the final report.

13 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs    
14 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Clinical Trial Landscape

    14.1 Drugs by Status
    14.2 Drugs by Phase
    14.3 Drugs by Route of Administration    
    14.4 Key Regulatory Events
15 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Scenario    
    15.1    Market Scenario - Key Insights    
    15.2    Market Scenario - Top 7 Markets  
         15.2.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size             
                  15.2.1.1 Market Size (2019-2024)    
                  15.2.1.2 Market Forecast (2025-2035)
         15.2.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                  15.2.2.1 Market Size by Therapies (2019-2024)
                  15.2.2.2 Market Forecast by Therapies (2024-2035)    
  15.3    Market Scenario - United States    
        15.3.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
              15.3.1.1 Market Size (2019-2024)    
                15.3.1.2 Market Forecast (2025-2035)
        15.3.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.3.2.1 Market Size by Therapies (2019-2024)
                15.3.2.2 Market Forecast by Therapies (2025-2035)
      15.3.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.4    Market Scenario - Germany    
           15.4.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
                  15.4.1.1 Market Size (2019-2024)        
                  15.4.1.2 Market Forecast (2025-2035)    
     15.4.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies    
15.4.2.1 Market Size by Therapies (2019-2024)    
                 15.4.2.2 Market Forecast by Therapies (2025-2035)
        15.4.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
    15.5    Market Scenario - France    
        15.5.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.5.1.1 Market Size (2019-2024)    
                 15.5.1.2 Market Forecast (2025-2035)    
     15.5.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies    
                 15.5.2.1 Market Size by Therapies (2019-2024)    
                 15.5.2.2 Market Forecast by Therapies (2025-2035)
        15.5.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview 
    15.6    Market Scenario – United Kingdom
        15.6.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                  15.6.1.1 Market Size (2019-2024)    
                 15.6.1.2 Market Forecast (2025-2035)
         15.6.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.6.2.1 Market Size by Therapies (2019-2024)
          15.6.2.2 Market Forecast by Therapies (2025-2035)
     15.6.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.7    Market Scenario – Italy
            15.7.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.7.1.1 Market Size (2019-2024)    
         15.7.1.2 Market Forecast (2025-2035)
          15.7.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.7.2.1 Market Size by Therapies (2019-2024)
                  15.7.2.2 Market Forecast by Therapies (2025-2035)
          15.7.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview 
15.8    Market Scenario - Spain
            15.8.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.8.1.1 Market Size (2019-2024)
         15.8.1.2 Market Forecast (2025-2035)    
         15.8.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.8.2.1 Market Size by Therapies (2019-2024)    
                 15.8.2.2 Market Forecast by Therapies (2025-2035)
     15.8.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
 15.9    Market Scenario - Japan    
            15.9.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
          15.9.1.1 Market Size (2019-2024)    
                 15.9.1.2 Market Forecast (2025-2035)    
      15.9.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies 
                  15.9.2.1 Market Size by Therapies (2019-2024)
                  15.9.2.2 Market Forecast by Therapies (2025-2035)
         15.9.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Access and Reimbursement Overview
16 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Recent Events and Inputs From Key Opinion Leaders
17 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market - SWOT Analysis    

   17.1    Strengths    
   17.2    Weaknesses    
   17.3    Opportunities    
   17.4    Threats         
 18 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Strategic Recommendation
 19 Appendix

Metabolic Dysfunction-Associated Steatohepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials